Previous 10 | Next 10 |
Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will participate in the following upcoming conferences: BIO Digital 2021 Form...
Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately. ...
— Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs — Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA&...
It has been 13 months since we last looked at small early stage developmental firm called Exicure. The company's development efforts originate from the proprietary Spherical Nucleic Acid, or SNA, technology, and it has a couple of compounds in development. A full analysis follows ...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have utilized Exicure’s licensed first generation gold-nanoparticle SN...
Exicure (XCUR): FY GAAP EPS of -$0.28 misses by $0.02.Revenue of $16.6M (+1176.9% Y/Y) misses by $2.36M.Shares +5.15%.Press Release For further details see: Exicure EPS misses by $0.02, misses on revenue
– Granted two Fast Track designations for cavrotolimod (AST-008) from the U.S. Food and Drug Administration (FDA) in January 2021 and an Orphan Drug Designation in March 2021 – Commenced IND-enabling studies on XCUR-FXN Friedreich’s ataxia in late 2020 ...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors. “We are ple...
The FDA has granted an Orphan Drug Designation to Exicure's (XCUR) cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma ((MCC)).Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved. FDA ha...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its clinical product candidate, cavr...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...